Differential regulation of CD4+ T helper cell responses by curcumin in experimental autoimmune encephalomyelitis

Journal of Nutritional Biochemistry

Volumn 23, Issue 11, 2012, Pages 1498-1507

  Kanakasabai, Saravanan ^a   Casalini, Eli ^a   Walline, Crystal C ^a   Mo, Caiqing ^a   Chearwae, Wanida ^a   Bright, John J ^a,b  

^a METHODIST RESEARCH INSTITUTE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmune disease; Curcumin; EAE MS; Inflammation; Nutraceuticals; Th1 cell

Indexed keywords

CURCUMIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR FOXP3;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; HELPER CELL; IN VITRO STUDY; LYMPHOID ORGAN; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SECRETION; REGULATORY T LYMPHOCYTE; SPLEEN CELL; TH2 CELL; TISSUE LEVEL; UPREGULATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CURCUMIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENCEPHALOMYELITIS; FEMALE; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-17; INTERLEUKIN-23; MICE; MICE, INBRED C57BL; NERVOUS SYSTEM AUTOIMMUNE DISEASE, EXPERIMENTAL; SPLEEN; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY;

CURCUMA LONGA; MUS;

EID: 84867719585     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2011.10.002     Document Type: Article

References (48)

1. Lodha R., Bagga A. Traditional Indian systems of medicine. Ann Acad Med Singapore 2000, 29:37-41.
2. Srimal R.C., Dhawan B.N. Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. J Pharm Pharmacol 1973, 25:447-452.
3. Araujo C.C., Leon L.L. Biological activities of Curcuma longa L. Mem Inst Oswaldo Cruz 2001, 96:723-728.
4. Claeson P., Panthong A., Tuchinda P., Reutrakul V., Kanjanapothi D., Taylor W.C., et al. Three non-phenolic diarylheptanoids with anti-inflammatory activity from Curcuma xanthorrhiza. Planta Med 1993, 59:451-454.
5. Mukhopadhyay A., Basu N., Ghatak N., Gujral P.K. Anti-inflammatory and irritant activities of curcumin analogues in rats. Agents Actions 1982, 12:508-515.
6. Surh Y. Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutat Res 1999, 428:305-327.
7. Sreejayan, Rao M.N. Curcuminoids as potent inhibitors of lipid peroxidation. J Pharm Pharmacol 1994, 46:1013-1016.
8. Chan M.M., Huang H.I., Fenton M.R., Fong D. In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties. Biochem Pharmacol 1998, 55:1955-1962.
9. Kakar S.S., Roy D. Curcumin inhibits TPA induced expression of c-fos, c-jun and c-myc proto-oncogenes messenger RNAs in mouse skin. Cancer Lett 1994, 87:85-89.
10. Surh Y.J., Chun K.S., Cha H.H., Han S.S., Keum Y.S., Park K.K., et al. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res 2001, 480-481:243-268.
11. Kang B.Y., Chung S.W., Chung W., Im S., Hwang S.Y., Kim T.S. Inhibition of interleukin-12 production in lipopolysaccharide-activated macrophages by curcumin. Eur J Pharmacol 1999, 384:191-195.
12. Kang B.Y., Song Y.J., Kim K.M., Choe Y.K., Hwang S.Y., Kim T.S. Curcumin inhibits Th1 cytokine profile in CD4+ T cells by suppressing interleukin-12 production in macrophages. Br J Pharmacol 1999, 128:380-384.
13. Donoghue S., Greenlees C. Drugs in development for the treatment of multiple sclerosis: antigen non-specific therapies-an update. Expert Opin Investig Drugs 2000, 9:167-171.
14. Dean G. How many people in the world have multiple sclerosis?. Neuroepidemiology 1994, 13:1-7.
15. Clegg A., Bryant J. Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness. Expert Opin Pharmacother 2001, 2:623-639.
16. Wingerchuk D.M., Lucchinetti C.F., Noseworthy J.H. Multiple sclerosis: current pathophysiological concepts. Lab Invest 2001, 81:263-281.
17. Martin R., McFarland H.F., McFarlin D.E. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992, 10:153-187.
18. O'Connor K.C., Bar-Or A., Hafler D.A. The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. J Clin Immunol 2001, 21:81-92.
19. Gironi M., Bergami A., Brambilla E., Ruffini F., Furlan R., Comi G., et al. Immunological markers in multiple sclerosis. Neurol Sci 2000, 21:S871-S875.
20. Gold R., Hartung H.P., Toyka K.V. Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today 2000, 6:88-91.
21. Owens T., Sriram S. The immunology of multiple sclerosis and its animal model, experimental allergic encephalomyelitis. Neurol Clin 1995, 13:51-73.
22. Bettelli E., Sullivan B., Szabo S.J., Sobel R.A., Glimcher L.H., Kuchroo V.K. Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J Exp Med 2004, 200:79-87.
23. Trinchieri G., Pflanz S., Kastelein R.A. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003, 19:641-644.
24. Trembleau S., Germann T., Gately M.K., Adorini L. The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol Today 1995, 16:383-386.
25. Nicoletti F., Patti F., Cocuzza C., Zaccone P., Nicoletti A., Di Marco R., et al. Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis. J Neuroimmunol 1996, 70:87-90.
26. Zhang G., Ghosh S. Molecular mechanisms of NF-kappaB activation induced by bacterial lipopolysaccharide through Toll-like receptors. J Endotoxin Res 2000, 6:453-457.
27. Darnell J.E., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264:1415-1421.
28. Bright J.J., Rodriguez M., Sriram S. Differential influence of interleukin-12 in the pathogenesis of autoimmune and virus-induced central nervous system demyelination. J Virol 1999, 73:1637-1639.
29. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748.
30. Ramirez-Tortosa M.C., Mesa M.D., Aguilera M.C., Quiles J.L., Baro L., Ramirez-Tortosa C.L., et al. Oral administration of a turmeric extract inhibits LDL oxidation and has hypocholesterolemic effects in rabbits with experimental atherosclerosis. Atherosclerosis 1999, 147:371-378.
31. Lim G.P., Chu T., Yang F., Beech W., Frautschy S.A., Cole G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001, 21:8370-8377.
32. Kim D.S., Park S.Y., Kim J.K. Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from betaA(1-42) insult. Neurosci Lett 2001, 303:57-61.
33. Joe B., Rao U.J., Lokesh B.R. Presence of an acidic glycoprotein in the serum of arthritic rats: modulation by capsaicin and curcumin. Mol Cell Biochem 1997, 169:125-134.
34. Deodhar S.D., Sethi R., Srimal R.C. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res 1980, 71:632-634.
35. Natarajan C., Bright J.J. Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. J Immunol 2002, 168:6506-6513.
36. Xie L., Li X.K., Funeshima-Fuji N., Kimura H., Matsumoto Y., Isaka Y., et al. Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production. Int Immunopharmacol 2009, 9:575-581.
37. Maier E., Kurz K., Jenny M., Schennach H., Ueberall F., Fuchs D. Food preservatives sodium benzoate and propionic acid and colorant curcumin suppress Th1-type immune response in vitro. Food Chem Toxicol 2010, 48:1950-1956.
38. Polak P.E., Kalinin S., Dello Russo C., Gavrilyuk V., Sharp A., Peters J.M., et al. Protective effects of a peroxisome proliferator-activated receptor-beta/delta agonist in experimental autoimmune encephalomyelitis. J Neuroimmunol 2005, 168:65-75.
39. Di Rosa F., Francesconi A., Di Virgilio A., Finocchi L., Santilio I., Barnaba V. Lack of Th2 cytokine increase during spontaneous remission of experimental allergic encephalomyelitis. Eur J Immunol 1998, 28:3893-3903.
40. Zhang M., Deng C.S., Zheng J.J., Xia J. Curcumin regulated shift from Th1 to Th2 in trinitrobenzene sulphonic acid-induced chronic colitis. Acta Pharmacol Sin 2006, 27:1071-1077.
41. Cong Y., Wang L., Konrad A., Schoeb T., Elson C.O. Curcumin induces the tolerogenic dendritic cell that promotes differentiation of intestine-protective regulatory T cells. Eur J Immunol 2009, 39:3134-3146.
42. Bhattacharyya S., Md Sakib Hossain D., Mohanty S., Sankar Sen G., Chattopadhyay S., Banerjee S., et al. Curcumin reverses T cell-mediated adaptive immune dysfunctions in tumor-bearing hosts. Cell Mol Immunol 2010, 7:306-315.
43. Chearwae W., Bright J.J. 15-deoxy-Delta(12,14)-prostaglandin J(2) and curcumin modulate the expression of toll-like receptors 4 and 9 in autoimmune T lymphocyte. J Clin Immunol 2008, 28:558-570.
44. Kim G.Y., Kim K.H., Lee S.H., Yoon M.S., Lee H.J., Moon D.O., et al. Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF-kappa B as potential targets. J Immunol 2005, 174:8116-8124.
45. Wang H.M., Zhao Y.X., Zhang S., Liu G.D., Kang W.Y., Tang H.D., et al. PPARgamma agonist curcumin reduces the amyloid-beta-stimulated inflammatory responses in primary astrocytes. J Alzheimers Dis 2010, 20:1189-1199.
46. Natarajan C., Bright J.J. Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes Immun 2002, 3:59-70.
47. Natarajan C., Muthian G., Barak Y., Evans R.M., Bright J.J. Peroxisome proliferator-activated receptor-gamma-deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis. J Immunol 2003, 171:5743-5750.
48. Thompson P.W., Bayliffe A.I., Warren A.P., Lamb J.R. Interleukin-10 is upregulated by nanomolar rosiglitazone treatment of mature dendritic cells and human CD4+ T cells. Cytokine 2007, 39:184-191.